Publication | Closed Access

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

OncologyPhase 2BPathologyBronchial NeoplasmAfatinib Versus GefitinibCancer TreatmentMedicineRadiation OncologyLung CancerMolecular OncologyLux-lung 7